General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform

News provided by

Nov 12, 2025, 10:00 ET

- The collaboration will leverage General Proximity's OmniTAC^™ platform to identify and advance next generation induced proximity agents for high value oncology targets.

- Induced proximity medicines, powered by the OmniTAC^™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins.

- General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.

SAN FRANCISCO, Nov. 12, 2025 /PRNewswire/ -- General Proximity, a biotechnology company discovering and developing the next generation of induced proximity medicines, today announced a strategic multi-target collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute in Boston to apply General Proximity's proprietary OmniTAC^™ discovery platform to oncology programs of interest to Daiichi Sankyo.

General Proximity Multi-Target Collaboration with Daiichi Sankyo

Induced proximity medicines enable the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets. The approach uses small molecules to bring two proteins into close physical proximity and subsequently induce a desired therapeutic effect. The OmniTAC^™ platform allows unbiased screening for effector proteins capable of modulating disease-relevant targets, offering a powerful and differentiated approach to drug discovery.

"Daiichi Sankyo is a leader in oncology research and development, and we are excited to work with such a strong collaborator," said Armand Cognetta, Founder & Chief Executive Officer of General Proximity. "This agreement represents an important validation of our novel induced proximity approach and highlights the potential of our OmniTAC^™ discovery platform to deliver innovative solutions for patients."

Under the terms of the collaboration, General Proximity will leverage OmniTAC^™ to discover and characterize novel effector-target pairs with the potential to generate first-in-class therapeutic candidates.

In parallel with this collaboration, General Proximity will continue to expand the reach of its OmniTAC™ platform by leveraging the precise control of proximity to address undruggable targets across multiple disease areas. In addition to oncology, the company is advancing programs in cardiometabolic disease, neurodegeneration, and longevity, underscoring its commitment to translating breakthrough science into transformative therapies for patients worldwide.

About General Proximity
General Proximity is a biotechnology company advancing next-generation induced proximity medicines. Its proprietary OmniTAC^™ platform enables unbiased identification of effector proteins capable of modulating disease-relevant targets, unlocking new opportunities across oncology and other therapeutic areas. The company is advancing multiple preclinical programs generated by the OmniTAC^TMplatform.

SOURCE General Proximity